secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001641172-25-009570
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated
--------------------------------------------------------------------------------

- Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.
- Cash and equivalents $2.9M as of 2025-03-31; company expects funding into late Q2 2025 only.
- First trial site initiated for Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.
- Abstract for OVATION 2 updated survival analysis accepted for oral presentation at 2025 ASCO Annual Meeting.
- Appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer effective 2025-02-18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/0001641172-25-009570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer